Optimizing Pipeline Performance - Maximizing Future Sales Opportunities through Pipeline Optimization & Benchmarking Strategies
出 版 商：CBR Pharma Insights
出版日期：2010/03/15
頁 數：60頁
文件格式：PDF
價 格：
USD 3,900 (Single-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
Optimizing Pipeline Performance - Maximizing Future Sales Opportunities through Pipeline Optimization & Benchmarking Strategies
Summary
In today’s pharmaceutical industry, optimizing pipeline performance is more important than ever before. With major patent expirations looming, an increase in competition coming from generics, healthcare reform taking shape, and a greater amount of scrutiny being seen with new drug approvals, having an efficient R&D process is crucial to a company’s future success.
This report assesses the key issues impacting pharmaceutical product development, while providing insight & analysis into the key strategies being used today to optimize pipeline performance. CBR Pharma Insights also examines how the top companies have laid out their research & development efforts and which therapeutic areas are seeing the most activity overall.
Scope
- Key issues affecting pharmaceutical company pipelines in 2010
- Optimizing pipeline performance
- Benchmarking the top 10 pharmaceutical companies pipelines
- Snapshots of top company pipelines
Reasons to buy
- Gain an understanding of the key issues impacting the pharmaceutical industry which have lead some to say that there is currently an “R&D crisis” taking place in the industry
- Learn about the strategies being employed by the top pharmaceutical companies to maximize their pipeline and drive future revenues
- Benefit from case study analysis and key company examples designed to best support your pipeline decision making
- Gain insight into which therapeutic areas are showing the greatest amount of R&D activity and by which of your competitors
- Through company benchmarking and historical assessments, examine the key trends in pipeline optimization
Summary
In today’s pharmaceutical industry, optimizing pipeline performance is more important than ever before. With major patent expirations looming, an increase in competition coming from generics, healthcare reform taking shape, and a greater amount of scrutiny being seen with new drug approvals, having an efficient R&D process is crucial to a company’s future success.
This report assesses the key issues impacting pharmaceutical product development, while providing insight & analysis into the key strategies being used today to optimize pipeline performance. CBR Pharma Insights also examines how the top companies have laid out their research & development efforts and which therapeutic areas are seeing the most activity overall.
Scope
- Key issues affecting pharmaceutical company pipelines in 2010
- Optimizing pipeline performance
- Benchmarking the top 10 pharmaceutical companies pipelines
- Snapshots of top company pipelines
Reasons to buy
- Gain an understanding of the key issues impacting the pharmaceutical industry which have lead some to say that there is currently an “R&D crisis” taking place in the industry
- Learn about the strategies being employed by the top pharmaceutical companies to maximize their pipeline and drive future revenues
- Benefit from case study analysis and key company examples designed to best support your pipeline decision making
- Gain insight into which therapeutic areas are showing the greatest amount of R&D activity and by which of your competitors
- Through company benchmarking and historical assessments, examine the key trends in pipeline optimization
Executive Summary
Key issues affecting pharmaceutical company pipelines in 2010
R&D productivity, budgets & cost cutting
Is there a “Productivity Crisis”
Going biotech
The toughening regulatory & pricing environments
Optimizing pipeline performance
Introduction
The M&A influence
Externalization
Restructuring R&D
More rigorous portfolio management
Utilizing emerging markets
Benchmarking the top 10 pharmaceutical companies pipelines
2009 approval analysis
R&D spend
Pipeline candidate analysis
Total number by company
Therapeutic area analysis
Company pipeline snapshots
Pfizer
GlaxoSmithKline
Sanofi-aventis
Merck
Novartis
AstraZeneca
Johnson & Johnson
Roche
Eli Lilly
Bristol-Myers Squibb
Appendix
Sources
Methodology
Key issues affecting pharmaceutical company pipelines in 2010
R&D productivity, budgets & cost cutting
Is there a “Productivity Crisis”
Going biotech
The toughening regulatory & pricing environments
Optimizing pipeline performance
Introduction
The M&A influence
Externalization
Restructuring R&D
More rigorous portfolio management
Utilizing emerging markets
Benchmarking the top 10 pharmaceutical companies pipelines
2009 approval analysis
R&D spend
Pipeline candidate analysis
Total number by company
Therapeutic area analysis
Company pipeline snapshots
Pfizer
GlaxoSmithKline
Sanofi-aventis
Merck
Novartis
AstraZeneca
Johnson & Johnson
Roche
Eli Lilly
Bristol-Myers Squibb
Appendix
Sources
Methodology
